Eleison to leverage BullFrog Data Networks™ to enhance patient clustering and safety analysis in glufosfamide clinical trialsGAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmace ...

GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025. At both ...

GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission ...

GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's forme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to Commission File Number 001-41600 BULLFROG AI HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 84-4786155 (State or other j ...

GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts. Dr. García-Rivera’s pre ...

Core Viewpoint - BullFrog AI Holdings, Inc. has successfully closed a definitive agreement for the purchase and sale of 1,565,000 shares of common stock and common warrants, raising approximately $3.13 million in gross proceeds from the offering [1][2]. Group 1: Offering Details - The offering includes a registered direct offering and a concurrent private placement, with a combined purchase price of $2.00 per share [1]. - The common warrants have an exercise price of $2.00 per share, are initially exercisable six months from issuance, and will expire five years from the initial exercise date [1]. - The shares and warrants will be issued under an effective shelf registration statement previously filed with the SEC [3]. Group 2: Financial and Legal Aspects - The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds from the exercise of the warrants and before deducting placement agent fees and other expenses [2]. - WallachBeth Capital, LLC acted as the sole placement agent for the offering, while Sheppard, Mullin, Richter & Hampton LLP served as counsel to the placement agent [2]. Group 3: Company Background - WallachBeth Capital provides a range of capital markets and investment banking services, particularly to the healthcare sector, including initial public offerings and private transactions [4].

Core Viewpoint - BullFrog AI Holdings, Inc. has successfully closed a definitive agreement for the purchase and sale of 1,565,000 shares of common stock and common warrants, raising approximately $3.13 million in gross proceeds through a registered direct offering and a concurrent private placement at a combined purchase price of $2.00 per share [1][2]. Group 1: Offering Details - The offering includes 1,565,000 shares of common stock and common warrants to purchase an equal number of shares, with an exercise price of $2.00 per share [1]. - The warrants are initially exercisable six months from the issuance date and will expire five years from that date [1]. - The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds from the exercise of the warrants and before deducting placement agent fees and other expenses [2]. Group 2: Regulatory Compliance - The shares and pre-funded warrants will be issued under an effective shelf registration statement on Form S-3, previously filed with the SEC [3]. - The common warrants issued in the private placement are offered under an exemption from registration requirements and have not been registered under the Securities Act [3]. Group 3: Company Overview - BullFrog AI is a technology-enabled drug development company utilizing AI and machine learning to enhance the development of pharmaceuticals and biologics [4]. - The company employs its proprietary bfLEAP(TM) platform to analyze biological, clinical, and real-world data, aiming to streamline data analytics and reduce development costs by decreasing failure rates in therapeutics [4].

JERSEY CITY, N.J., Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565, ...

GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direc ...